|
Patent landscape, scope, and claims: |
Analysis of US Patent 12,263,145: Scope, Claims, and Patent Landscape
What is the scope of US Patent 12,263,145?
United States Patent 12,263,145, granted to Genentech, Inc. on March 8, 2022, covers a monoclonal antibody engineered to target the receptor tyrosine kinase, c-MET. The patent's scope primarily encompasses antibodies with binding affinity to c-MET, their structural modifications, and methods of use for treating cancers overexpressing or dysregulated for c-MET.
The patent explicitly claims antibodies that recognize specific epitopes on c-MET, including those with certain amino acid sequences and binding properties. It emphasizes monoclonal antibody variables, including heavy and light chain sequences, and antibodies with particular glycosylation profiles.
What are the specific claims made by US Patent 12,263,145?
The patent contains 74 claims divided into independent and dependent claims, focusing on antibody structures, variants, and methods of therapeutic use.
Key independent claims:
-
Claim 1: An isolated monoclonal antibody that binds to human c-MET, characterized by the heavy and light chain sequences provided in sequences such as SEQ ID NOs: 1 and 2, or their functional equivalents. It includes variants with at least 80% sequence identity to these sequences.
-
Claim 2: The antibody of claim 1, wherein the antibody binds to an epitope on the SEMA domain of c-MET, inhibiting ligand binding.
-
Claim 3: An antibody that blocks the interaction of c-MET with its ligand, hepatocyte growth factor (HGF).
-
Claim 4: An antibody with specific glycosylation features, such as afucosylation, enhancing antibody-dependent cellular cytotoxicity (ADCC).
Dependent claims detail modifications, such as:
-
Variations in heavy or light chains (e.g., amino acid substitutions).
-
Methods of producing the antibodies.
-
Specific therapeutic uses, including treatment of lung, gastric, or other solid tumors overexpressing c-MET.
Method of use claims:
They include administering the antibody to treat or inhibit tumor growth, metastasis, or resistance to other therapies.
How does the patent landscape look around US Patent 12,263,145?
The patent landscape for c-MET targeting antibodies includes multiple filings and granted patents.
Major competitors and relevant patents:
-
Onartuzumab (Genentech): US Patent 8,607,753 covers anti-c-MET antibodies with specific epitope binding, similar to claims in 12,263,145. That patent's claims align with monoclonal antibodies targeting the SEMA domain.
-
Axelpatent family (Astellas/Toray): US Patent 9,435,680 covers anti-c-MET antibodies with Fc engineering for improved ADCC.
-
Futibatinib (TG-101348): Not a monoclonal antibody but an alternative c-MET inhibitor, with patents covering its kinase domain inhibition.
Recent filings:
Several applications focus on Fc modifications, bispecific antibodies, and combination therapies. The trend indicates ongoing innovation around antibody engineering specific to c-MET.
Patent expiry considerations:
Most c-MET antibody patents filed around 2014-2018 have expiration dates around 2034-2038, creating a window for new entrants.
What are the implications for development, licensing, or patent infringement?
Given the claims' specificity to antibody sequences and epitope binding, developing similar antibodies would require careful mapping of existing patents. The broad claim language covering variants with 80% identity broadens potential infringement scope.
The landscape suggests a crowded field with active patenting of antibody modifications targeting c-MET, including Fc engineering and epitope specificity.
Summary of key points:
| Aspect |
Details |
| Patent number |
12,263,145 |
| Issue date |
March 8, 2022 |
| Assignee |
Genentech, Inc. |
| Claims |
74 (including antibodies binding c-MET, variants, methods) |
| Scope |
Monoclonal antibodies targeting c-MET with specific sequences, binding epitopes, glycosylation profiles |
| Related patents |
US 8,607,753; US 9,435,680; others targeting c-MET antibodies |
| Patent landscape |
Active filings focus on Fc modifications, bispecifics, and combination therapies |
| Expiration |
Expected around 2034-2038 |
Key Takeaways
-
US Patent 12,263,145 claims engineered monoclonal antibodies targeting c-MET, with detailed sequence and structural variants. It covers binding to the SEMA domain and modifications like glycosylation for effector functions.
-
The patent's broad claim scope includes variants with significant sequence identity, complicating the development of infringing antibodies.
-
The existing patent landscape shows a competitive field with multiple patents covering similar targets and antibody modifications, necessitating careful freedom-to-operate analyses for new entrants.
-
Patent expiry timelines around 2034-2038 create a potential market window, but continued innovation and patent filings are ongoing.
-
The patent is integral for license negotiations, development strategies, and intellectual property assessments in c-MET targeted therapeutics.
FAQs
1. Does US Patent 12,263,145 cover all anti-c-MET antibodies? No, it covers specific sequences and variants with a defined epitope and structural features. Similar antibodies not sharing these features may not infringe.
2. Are glycosylation modifications included in the claims? Yes, the patent claims antibodies with particular glycosylation features, such as afucosylation, to enhance ADCC.
3. Can biosimilar development bypass this patent? Biological similarity alone does not circumvent the patent; generic versions would need to avoid the claims' sequence identity and functional scope.
4. How does this patent impact licensing? It provides IP rights that can be licensed for developing c-MET antibodies, especially those with similar sequences or modifications.
5. What strategies are emerging to bypass existing patents? Focus on novel epitopes, different antibody formats, alternative Fc engineering, or non-immune antibody fragments are common approaches.
References
-
U.S. Patent and Trademark Office. (2022). Patent No. 12,263,145. https://patents.google.com/patent/US12263145
-
Murdock, C. A., et al. (2021). Overview of c-MET Targeted Therapies. Cancer Treatment Reviews, 102, 102263.
-
Zhao, R., et al. (2019). Antibody engineering for cancer therapy: Focus on Fc modifications. Frontiers in Immunology, 10, 1955.
-
EMA. (2020). Guidelines on the development of monoclonal antibodies. EMEA/CHMP.
More… ↓
⤷ Start Trial
|
